William Blair Remains a Hold on FibroGen (FGEN)

In a report released today, Andy Hsieh from William Blair reiterated a Hold rating on FibroGen (FGEN – Research Report). The company’s shares closed yesterday at $0.31.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

According to TipRanks, Hsieh is a 4-star analyst with an average return of 4.6% and a 41.11% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Skye Bioscience, Cardiff Oncology, and Lantheus.

FibroGen has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.

Based on FibroGen’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $17.98 million. In comparison, last year the company earned a revenue of $27.14 million and had a GAAP net loss of $56.23 million

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FGEN in relation to earlier this year. Most recently, in March 2025, Thane Wettig, the CEO of FGEN bought 145,000.00 shares for a total of $49,300.00.